Vaxil Bio Ltd.
VXLLF
$0.008
$0.00233.33%
| Weiss Ratings | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.58 | |||
| Price History | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | 33.33% | |||
| 2-Year Total Return | 0.00% | |||
| 3-Year Total Return | -77.84% | |||
| 5-Year Total Return | -94.27% | |||
| 52-Week High % Change | -76.47% | |||
| 52-Week Low % Change | 166.67% | |||
| Price | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.03 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | May 09, 2024 | |||
| 52-Week High Price (Date) | May 07, 2024 | |||
| Valuation | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 957.04K | |||
| Enterprise Value | 583.25K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -68.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 2.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | 13.59 | |||
| Enterprise Value/EBIT | -3.22 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 136.98M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 3400 One First Canadian Place Toronto, ON M5X 1A4 | |||
| Website | vaxil-bio.com | |||
| Country | Canada | |||
| Year Founded | 2006 | |||
| Profitability | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -8.84% | |||
| Return on Equity | -- | |||
| Income Statement | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | 23.20K | |||
| EBIT (TTM) | -97.80K | |||
| Net Income (TTM) | -95.60K | |||
| Net Income Avl. to Common (TTM) | -95.60K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -71.77% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | -50.00% | |||
| Balance Sheet | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 396.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 607.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 546.30K | |||
| Current Ratio (Q) | 10.000 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 607.00K | |||
| Total Current Liabilities (Q) | 60.70K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 60.70K | |||
| Total Common Equity (Q) | 546.30K | |||
| Cash Flow | VXLLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -182.70K | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -347.10K | |||
| Levered Free Cash Flow (TTM) | -310.30K | |||
| Cash from Operations (TTM) | -165.10K | |||
